Hjem › Non-Hodgkins lymfom › Texas › Houston
Kliniske studier for Non-Hodgkins lymfom i Houston, TX
31 studier for Non-Hodgkins lymfom søker deltakere på steder i og rundt Houston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
- Md Anderson Cancer Center, Houston
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
RekruttererFase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RekruttererFase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RekruttererFase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservasjonsstudie
- Texas Children's Hospital, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruttererFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- MD Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruttererFase 1
- Baylor College of Medicine, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Md Anderson Cancer Center, Houston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
RekruttererFase 1/2
- Research Site, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RekruttererFase 2
- Research Site, Houston
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RekruttererFase 1
- The University of Texas MD Anderson Cancer Center, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RekruttererFase 1
- Clinical Trial Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruttererFase 3
- MD Anderson Cancer Center, Houston
Personalized NK Cell Therapy in CBT
RekruttererFase 2
- M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservasjonsstudie
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
RekruttererFase 1
- Harris Health System - Ben Taub General Hospital/Smith Clinic, Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
- og 1 flere
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
RekruttererFase 2
- M D Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruttererFase 1
- MD Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruttererFase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RekruttererFase 1
- Harris Health System (includes ben Taub General Hospital and Smith), Houston
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruttererFase 4
- University of Texas MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruttererFase 4
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekruttererFase 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RekruttererFase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RekruttererFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Non-Hodgkins lymfom-studier i andre byer
- New York City, NY31 studier
- Boston, MA26 studier
- Nashville, TN21 studier
- Philadelphia, PA20 studier
- Baldwin Park, CA19 studier
- Washington, DC18 studier
- Chicago, IL18 studier
- Atlanta, GA18 studier
- Milwaukee, WI18 studier
- Columbus, OH18 studier
- Dallas, TX17 studier
- Seattle, WA16 studier
Andre studier i Houston
- Ikke-småcellet lungekreft145 studier
- Brystkreft126 studier
- Kreft (alle typer)121 studier
- Metastatisk kreft104 studier
- Kolorektal kreft102 studier
- Eggstokkreft89 studier
- Akut myelogen leukemi85 studier
- Lungekreft78 studier
- Prostatakreft76 studier
- Endometriekreft68 studier
- Pankreaskreft61 studier
- Melanom59 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.